Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

FlareReboot47 Apr. 25 at 6:29 AM

$PMN Clinical Timeline: At the Bloom Burton & Co. Healthcare Investor Conference (April 21–22), CEO Neil Warma outlined the roadmap for PMN310 (their lead Alzheimer’s candidate):

1 · Reply

Blueknoser Apr. 24 at 10:32 AM

$PMN insider's are still buying: https://www.promisneurosciences.com/investors/sec-filings##document-766-0001104659-26-047977-2

1 · Reply

Blueknoser Apr. 23 at 8:22 PM

$PMN the current stock manipulation is to rid the retail investors of their shares; patience is a virtue as they say! A couple of months, even just weeks, there's going to be a watershed moment! Hang in there!!

0 · Reply

Cellsci Apr. 21 at 1:51 PM

$PMN

0 · Reply

Misterx69 Apr. 21 at 12:22 AM

$PMN https://www.tradingview.com/news/tmx_newsfile:7fafad82d094b:0-promis-neurosciences-invited-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference/

0 · Reply

oneyedjacks Apr. 20 at 3:08 PM

$PMN They need cash. $6 m left and burning $10M per qtr.

1 · Reply

TradeWoFear Apr. 17 at 10:40 PM

$PMN Forecasted by CNN Business!!!! very interesting , as low is 200% from here and up to 330% !!!! i will go with 200% ... very extreme low float , with few order this can rocket up 200% easily imo...., i will leave that last guess to you!!

0 · Reply

TradeWoFear Apr. 17 at 4:29 PM

$PMN forcasted target for $34 , I can see the history twice rocket up for $26 that 100% up from here … imo it has a great setup to rocket up soon be ready just little positive news with extreme low float can double up imo…

0 · Reply

AtlasAnalysis Apr. 16 at 2:42 PM

$PMN upside increases if it regains 12.35-.40 support

0 · Reply

sangysmith Apr. 14 at 11:45 AM

$PMN the conference for ALZ in july early q3 coincide with interim results of phase 1b. Pure coincidence or promis knew this earlier.

0 · Reply

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Mar 25, 2026, 8:00 AM EDT - 4 weeks ago

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

Mar 18, 2026, 8:00 AM EDT - 5 weeks ago

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

Feb 11, 2026, 9:30 AM EST - 2 months ago

ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 2 months ago

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 30, 2026, 8:00 AM EST - 3 months ago

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Dec 18, 2025, 7:30 AM EST - 4 months ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 10, 2025, 7:30 AM EST - 4 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 2, 2025, 3:25 PM EST - 5 months ago

ProMIS Neurosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 7:30 AM EST - 5 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:00 AM EST - 5 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 5 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Nov 12, 2025, 7:00 AM EST - 5 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 10, 2025, 11:00 AM EST - 5 months ago

ProMIS Neurosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 4:05 PM EST - 6 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 6 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 10, 2025, 12:30 PM EDT - 8 months ago

ProMIS Neurosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 9 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 9 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Feb 5, 2025, 1:30 PM EST - 1 year ago

ProMIS Neurosciences Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 2 years ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

FlareReboot47 Apr. 25 at 6:29 AM

$PMN Clinical Timeline: At the Bloom Burton & Co. Healthcare Investor Conference (April 21–22), CEO Neil Warma outlined the roadmap for PMN310 (their lead Alzheimer’s candidate):

1 · Reply

Blueknoser Apr. 24 at 10:32 AM

$PMN insider's are still buying: https://www.promisneurosciences.com/investors/sec-filings##document-766-0001104659-26-047977-2

1 · Reply

Blueknoser Apr. 23 at 8:22 PM

0 · Reply

Cellsci Apr. 21 at 1:51 PM

$PMN

0 · Reply

Misterx69 Apr. 21 at 12:22 AM

$PMN https://www.tradingview.com/news/tmx_newsfile:7fafad82d094b:0-promis-neurosciences-invited-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference/

0 · Reply

oneyedjacks Apr. 20 at 3:08 PM

$PMN They need cash. $6 m left and burning $10M per qtr.

1 · Reply

TradeWoFear Apr. 17 at 10:40 PM

0 · Reply

TradeWoFear Apr. 17 at 4:29 PM

0 · Reply

AtlasAnalysis Apr. 16 at 2:42 PM

$PMN upside increases if it regains 12.35-.40 support

0 · Reply

sangysmith Apr. 14 at 11:45 AM

$PMN the conference for ALZ in july early q3 coincide with interim results of phase 1b. Pure coincidence or promis knew this earlier.

0 · Reply

focafoca99 Apr. 13 at 3:33 PM

$PMN is announcing participation in the Bloom Burton healthcare conference while reiterating timing around its PRECISE-AD study milestones.

1 · Reply

newsfile_corp Apr. 13 at 11:30 AM

https://nfne.ws/290087 $PMN @bloomburton #Energy #Biotechnology #InvestmentBanking #Technology #NASDAQ #Investing

0 · Reply

sangysmith Apr. 13 at 6:21 AM

$PMN Are we in any of the below: Key 2026 Alzheimer's & Dementia Conferences 37th Global Conference of Alzheimer's Disease International (ADI): April 14–16, 2026 (Lyon, France) - Focuses on dementia care and global strategies. AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases: (Copenhagen, Denmark) - Focuses on cutting-edge research, trials, and treatments. American Academy of Neurology (AAN) Annual Meeting: April 18–22, 2026 (Chicago, IL/Online). Alzheimer's Association International Conference (AAIC): July 12–15, 2026 (London, UK/Online) - The world's largest conference on dementia science. Innovations and State of the Art in Alzheimer's & Dementia (ISAD-2026): September 7–8, 2026 (Paris, France).

0 · Reply

sangysmith Apr. 12 at 12:08 PM

$PMN Look at some of big companies spending on R&D. Interesting to see the number. One of them couls be the acquirer of promis neuroscience if PMN 310 turn out to be blockbuster.

1 · Reply

sangysmith Apr. 10 at 8:48 PM

$PMN Based on the below 2 more catalysts end of this year / early next year 04 nos in total know for 3 pipelines. Based on the most recent corporate updates from March 2026, both PMN267 and PMN442 are currently in the final stages of IND-enabling studies. While ProMIS Neurosciences has not yet set a definitive "first-patient-dosed" date for Phase 1, the timeline is becoming clearer following a major $75.5 million financing round in February 2026. Projected Timelines PMN267 (ALS/TDP-43): IND Submission: Anticipated for late 2026. Phase 1 Start: Expected in early 2027, following the successful clearance of the Investigational New Drug (IND) application. PMN442 (Parkinson’s/α-syn): IND Submission: Likely following a similar trajectory to PMN267, with a target for late 2026 or early 2027. Phase 1 Start: Expected mid-2027.

0 · Reply

Kgra Apr. 10 at 7:48 PM

$PMN showing stability

0 · Reply

sangysmith Apr. 9 at 8:11 PM

$PMN PMN311 (or PMN-311) is a preclinical amyloid-beta (Aβ) vaccine candidate being developed by ProMIS Neurosciences, Inc. (NASDAQ: PMN), a biotechnology company focused on neurodegenerative diseases. Key Details Target and Mechanism: It is designed as a preventive vaccine for Alzheimer's disease (AD). The vaccine uses an oligomer-specific epitope identified through ProMIS's proprietary platform, which selectively targets toxic misfolded oligomers of amyloid-beta (pathogenic molecular species) while avoiding healthy forms of the protein. Preclinical mouse vaccination studies have shown it induces antibody responses selective for these harmful oligomers. Development Stage: Preclinical (as of the latest available updates in 2025). The company continues to advance the program alongside its lead antibody candidate PMN310 (a humanized monoclonal antibody for treating AD) Purpose: Aimed at inducing an immune response to prevent or slow the progression of Alzheimer's

1 · Reply

sangysmith Apr. 8 at 5:09 AM

$PMN

2 · Reply